Different Histopathological Subtypes of Hodgkin Lymphoma Have Significantly Different Levels of FDG Uptake.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 969-969
Author(s):  
Martin Hutchings ◽  
Annika L. Jakobsen ◽  
Mads T. Hansen ◽  
Elisabeth Ralfkiaer ◽  
Lena Specht

Abstract Background: Functional imaging with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool in the staging of Hodgkin lymphoma (HL). FDG-PET enables quantitative information about the tumour metabolism, most commonly measured as the semiquantitative standardised uptake value (SUV). The aim of this study was to investigate if the level of FDG uptake varies between the different subtypes of HL. Methods: Sixty consecutive patients with newly diagnosed HL were prospectively included in the protocol. At least one lymph node biopsy was obtained from each patient and all patients underwent an FDG-PET/CT scan along with other staging procedures. The highest SUV in each patient (SUVmax/total) and in each affected region or organ (SUVmax) was recorded. Differences in SUVmax between histopathological subgroups were analysed with independent-samples student’s t-test and one-way analysis of variance (ANOVA). Results: 38 patients had nodular sclerosis (NS), 11 patients had mixed cellularity (MC), seven patients had nodular lymphocyte predominance (NLP) and four patients had classical HL, not otherwise specified (CHL-NOS). Mean SUVmax/total was 9.3 g/ml in NLP patients, 16.3 g/ml in NS patients, 20.8 g/ml in MC patients, and 19.5 g/ml in CHL-NOS patients (Figure 1). The difference between the histopathological subgroups was highly significant (ANOVA, p = 0.011). Out of 780 potential sites of disease (600 lymph node regions plus 180 organs), 208 sites were affected with HL. Mean SUVmax was 8.3 g/ml in the 12 sites affected with NLP, 11.2 g/ml in the 147 sites affected with NS, 14.6 g/ml in the 36 sites affected with MC, and 13.1 g/ml in the 13 sites affected with CHL-NOS (ANOVA, p = 0.011, Figure 2). Mean SUVmax in sites with NS was significantly higher than in sites with NLP (t-test, p = 0.042) and significantly lower than in sites with MC (t-test, p = 0.011). Conclusion: There is a significant difference in FDG/glucose uptake between the different histopathological subtypes of HL. The SUVs in NLP, NS and MC lymphomas are significantly different, while the uptake in CHL-NOS lymphomas resembles the uptake in MC lymphomas. SUV analysis is frequently used in situations where the qualitative evalutation of a site on FDG-PET is uncertain. In those situations, it is helpful to know that the level of uptake varies from subtype to subtype. Since the subtypes have different FDG metabolism, they should ideally be regarded separately in future studies of FDG-PET and FDG-PET/CT in HL. 1. Highest SUV anywhere in the body of each patient 1. Highest SUV anywhere in the body of each patient

2011 ◽  
Vol 93 (4) ◽  
pp. 545-550 ◽  
Author(s):  
Tamás Györke ◽  
Attila Kollár ◽  
Gyula Bottlik ◽  
Ágota Szepesi ◽  
Imre Bodó ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8046-8046
Author(s):  
Nicolas Mounier ◽  
Mark Bower ◽  
Michele Spina ◽  
Caroline Besson ◽  
Clara Schiantarelli ◽  
...  

8046 Background: The high prognostic value of FDG-PET/CT performed after 2 cycles of chemotherapy for HIV negative Hodgkin lymphoma (HL) is well known. However, experience with PET in HIV-related HL needs to be further studied as nodal FDG uptake can be observed in various opportunistic infections and AIDS-related conditions. Methods: A total of 45 consecutive HL patients (pts) were enrolled in 10 centers from the GECAT. There were 42 males and 3 females. Median age was 46 yo, range [26;64]. Median CD4 count was 391/mm3, range [33;1191]. Viral load was negative in 38 pts (84%) and uncontrolled in 5 pts (11%). Forthy three pts (96%) received concomitant HAART. HL was staged III-IV in 25 pts. International Prognostic Index scored 3-5 in 24 pts. All PET studies were performed after 2 ABVD cycles. They were scored, blinded to treatment outcome, according to the 5-point Deauville visual scale. It was considered as negative when scored 1-3 (i.e tumor FDG uptake less or equal than liver uptake) and positive when scored 4-5 (i.e. more than liver uptake or new lesions). Chemotherapy was not modified : 4-8 cycles of ABVD, as initially planned. Results: Overall, 35 pts (78%) achieved a CR after the end of treatment. Three pts received Involved Field Radiation Therapy. At a median follow-up of 18 months, 3 pts relapsed and 2 of them died from HL. The 2 yr OS and PFS were estimated at 94 and 90%, respectively. PET after 2 cycles of ABVD was negative in 40 pts (89%) and positive in 5 pts (11%). Patients with negative PET had a significantly better outcome than those with positive PET in term of 2 yr PFS (94% vs 60%, P=0.005), and 2 yr OS (100% vs 60%, P=0.0002). The negative predictive value was estimated at 97% and specificity at 93%. All patients who were PET-negative after the 2nd cycle stayed PET-negative after the 4th cycle and entered a durable CR. Conclusions: This largest study in HIV-positive HL showed that interim PET could play a central role in driving risk-tailored treatment. In further studies, de-escalation strategies should be tested for patients responding after 2 cycles of ABVD and those not reponding should be managed with intensive salvage strategies.


Toukeibu Gan ◽  
2008 ◽  
Vol 34 (4) ◽  
pp. 513-517 ◽  
Author(s):  
Takayoshi Aramoto ◽  
Koh-ichi Nakashiro ◽  
Hidetomo Nishikawa ◽  
Tomoki Sumida ◽  
Masao Miyagawa ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Yiping Shi ◽  
Lian Xu ◽  
Yinjie Zhu ◽  
Yining Wang ◽  
Ruohua Chen ◽  
...  

PurposeDifferentiating lymph node metastases (LNM) from peripheral ganglia by physiological prostate-specific membrane antigen (PSMA) uptake is challenging. Two tracers (68Ga-PSMA-11 and 18F-fluorodeoxyglucose [FDG]) metabolic uptake patterns were evaluated by positron emission tomography-computed tomography (PET-CT), searching for differences that could tell ganglia from LNM.MethodsDual 68Ga-PSMA-11 and 18F-FDG PET-CT data of 138 prostate cancer patients acquired from June 2018 to December 2019 were retrospectively evaluated. Ganglia and LNM with PSMA-11 uptake above local background were analyzed by the location and PSMA-11-PET and FDG-PET maximum standardized uptake value (SUVmax).ResultsPSMA-11-positive ganglia (n = 381) and LNM (n = 83) were identified in 138 and 58 patients, respectively. The LNM SUVmax of PSMA-11-PET (16.4 ± 14.8 vs 2.3 ± 0.7, P < 0.001) and FDG-PET (3.3 ± 3.2 vs 1.5 ± 0.5, P < 0.001) were higher than in ganglia. The probabilities of being an LNM in the low-potential (PSMA-11-PET SUVmax of <4.1 and FDG-PET SUVmax of <2.05), moderate-potential (PSMA-11-PET SUVmax of >4.1 and FDG-PET SUVmax of <2.05, or PSMA-11-PET SUVmax of <4.1 and FDG-PET SUVmax of >2.05), and high-potential (PSMA-11-PET SUVmax of >4.1 and FDG-PET SUVmax of >2.05) groups were 0.9% (3/334), 44.6% (37/83), and 91.5% (43/47), respectively (P < 0.001). The cervical and coeliac ganglia had higher PSMA-11 and FDG uptake than the sacral ganglia (P < 0.001 for all). LNM PSMA-11 and FDG uptake was similar in these three locations.ConclusionThe FDG-PET and PSMA-11-PET SUVmax, especially when combined, could well differentiate LNM from ganglia. The tracers uptake differed between cervical/coeliac and sacral ganglia, so the lesion location should be considered during image assessment.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21084-e21084
Author(s):  
Atsushi Kagimoto ◽  
Yasuhiro Tsutani ◽  
Yoshinori Handa ◽  
Takahiro Mimae ◽  
Yoshihiro Miyata ◽  
...  

e21084 Background: This study aimed to investigate the efficacy of the Deauville criteria, a 5-point visual scale criteria to assess the maximum standardized uptake value (SUVmax) of [18F]-fluoro-2-deoxy-D-glucose (FDG) on positron emission tomography (PET)/computed tomography (CT), in predicting lymph node metastasis and other pathological invasive characteristics of early-stage lung adenocarcinoma. Methods: In this retrospective study including 453 patients undergoing lobectomy or segmentectomy with lymph node dissection for clinical N0 lung adenocarcinoma with a whole size ≤ 3 cm between April 2011 and March 2019, the FDG-PET/CT scans were evaluated using the Deauville criteria to analyze the relationship of Deauville score with the clinicopathological characteristics and prognosis.The scoring method was as follows: Deauville score of 1, no FDG uptake by the primary tumor (same as background); Deauville score of 2, tumor FDG uptake that is the same as or weaker than that of mediastinum; Deauville score of 3, tumor FDG uptake that is stronger than that of mediastinum but same as or weaker than that of liver; Deauville score of 4, tumor FDG uptake that is moderately higher than that of liver; Deauville score of 5, tumor FDG uptake that is markedly stronger than that of liver. Results: The lymph node metastases were present in 0 (0%), 2 (1.1%), 6 (9.5%), 6 (15.8%), and 13 (15.7%) patients with Deauville scores of 1, 2, 3, 4 and 5, respectively. The pathological invasive characteristics (lymphatic, vascular, or visceral pleural invasion) were detected in 2 (2.4%), 17 (9.9%), 18 (28.6%), 23 (60.5%), and 54 (65.1%) patients, respectively. Similar results were found when the study cohort was analyzed according to the institutions where the FDG-PET/CT scans were performed. The 3-year recurrence-free survival was longer in the patients with a Deauville score of 1–2 (97.2%) than those with a Deauville score of 3 (86.2%, p < 0.001) or 4–5 (80.7%, p < 0.001). Conclusions: The 5-point-scale evaluation of the SUVmax on FDG-PET/CT using the Deauville score was useful in predicting not only lymph node metastasis but also other malignancy characteristics of early-stage lung adenocarcinoma.


2012 ◽  
Vol 33 (4) ◽  
pp. 439-444 ◽  
Author(s):  
Françoise J. Siepel ◽  
Wieger I. de Bruin ◽  
Eino B. van Duyn ◽  
Pascal Steenvoorde ◽  
Nils R.L. Wagenaar ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1390-1390
Author(s):  
Steven Le Gouill ◽  
Caroline Bodet-Milin ◽  
Françoise Kraeber-Bodere ◽  
Anne Moreau ◽  
Laurent Campion ◽  
...  

Abstract Introduction: Most lymphomas show a good FDG uptake, with significant difference in intensity according to different histopathological subtypes. Richter’s syndrome </DEL> (RS) is defined as the development of aggressive lymphoma in patients with low grade histopathological subtypes. Diagnosis requires histological findings. The aim of our study was to investigate prospectively FDG-PET/CT to guide biopsy in the diagnosis of aggressive transformation of low grade lymphomas. Material and methods: Thirty-eight patients, presenting clinical and/or biological signs of aggressive transformation were included. The 38 underwent FDG-PET/CT. FDG-PET/CT scans were analysed visually and semi-quantitatively with maximal standardised uptake value (SUVmax) normalised for body mass. Guided-biopsy was performed 4 weeks after FDG-PET/CT, in the abnormal focus showing the highest SUVmax and histopathological analysis was performed. Results: Histopathological analysis concluded to aggressive transformations in 17 cases (15 NHL and 2 Hodgkin diseases included one composite lymphoma) and low grade lymphomas in 21 cases. Size of lesions on CT was not predictive of RS (p=0.094). FDG-PET/CT images showed abnormal FDG uptake in the 38 included patients. SUVmax ranged from 11.7 to 41.2 in patients with Richter’s syndrome and from 1.7 to 17.0 in patients with no sign of transformation(p<0.0001). Gradient of SUVmax was significantly higher in patients with Richter’s syndrome (p<0.0001). A SUVmax threshold of 14.0 gave the better balance with sensitivity, specificity, predictive positive and negative values around 95.0%. This threshold of 14.0 correctly classified as transformed or not transformed 36/38 patients (94.7%). Conclusion: FDG-PET/CT imaging is a very relevant tools to detect aggressive transformation of low grade lymphomas and to guide biopsy.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Marco Enoch Lee ◽  
James Yuheng Jiang ◽  
Nicholas Mckay Parry ◽  
Deme Karikios ◽  
Robert Mansberg

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
I Koutagiar ◽  
A Georgakopoulos ◽  
A Pouli ◽  
A Sioni ◽  
S Giannouli ◽  
...  

Abstract Introduction There is increasing evidence that metabolic disease burden in lymphoma influence patients' outcome.However, the impact of disease severity on cardiovascular system remains unknown. Purpose To assess whether lymphoma is associated with arterial inflammation by examining the relationship between disease metabolic burden and arterial fluorodeoxyglucose (FDG) uptake. Methods Sixty-two patients (43 male, mean age 58±18 years) with Hodgkin (n=29) or non-Hodgkin lymphoma (n=33) before chemotherapy and two separate control groups of 14 and 16 healthy individuals for Hodgkin and non-Hodgkin population respectively, with similar age, sex and cardiovascular risk factors,underwent FDG position emission tomography (FDG-PET/CT) imaging.Disease severity was quantified by metabolic tumor volume (MTV) and total lesion glycolysis (TLG) corresponding to standard uptake values (SUV) ≥41% or ≥2.5 of maximum SUV within lymphoma regions, and aortic FDG uptake by target-to-background ratio (TBR). Serum high sensitivity-C-reactive protein (hs-CRP), white blood count (WBC), ratio of neutrophils to lymphocytes (N/L), albumin and lactic acid dehydrogenase (LDH) values were measured for patient group. Results MTV and TLG measurements correlated significantly with hs-CRP, WBC,N/L ratio,albumin and LDH table 1.Patients with non-Hodgkin or Hodgkin lymphoma had increased aortic TBR compared to controls (p=0.001 and p=0.023, respectively).Aortic TBR was higher in patients with stage III-IV disease compared to those with stage I-I (p=0.046).There were significant associations between aortic FDG uptake and MTV values, which remained significant after adjustment for confounders (β=0.353, p=0.001, adjusted R2=0.318 for MTV41%, β=0.442, p=0.001, adjusted R2=0.269 for MTV2.5), Figure 1. Conclusions Aortic wall FDG uptake is related with disease severity indicating a vascular effect of lymphoma, as well as a new potential role of molecular imaging in cardio-oncology for evaluating disease severity and its consequences to vascular beds with a single examination. Figure 1 Funding Acknowledgement Type of funding source: None


Sign in / Sign up

Export Citation Format

Share Document